デング熱用ワクチンの世界市場機会分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 11
1.1 List of Tables 16
1.2 List of Figures 18
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 20
2.3 Upcoming Related Reports 21
3 Disease Overview 22
3.1 Etiology and Pathophysiology 22
3.1.1 Etiology 22
3.1.2 Pathophysiology 25
3.2 Symptoms 28
3.3 Prognosis 31
4 Epidemiology 32
4.1 Disease Background 32
4.2 Risk Factors and Comorbidities 32
4.3 Global Trends 35
4.3.1 Incidence and Geographic Distribution 35
4.3.2 Dengue Periodic and Seasonal Patterns 37
4.3.3 Dengue Serotypes 38
4.4 Forecast Methodology 39
4.4.1 Sources Used 41
4.4.2 Sources Not Used 44
4.4.3 Forecast Assumptions and Methods 44
4.5 Epidemiological Forecast for Dengue (2013-2023) 47
4.5.1 Reported Laboratory-Confirmed Dengue Cases 47
4.5.2 Sex-Specific Distribution of Reported Laboratory-Confirmed Dengue Cases 49
4.5.3 Age-Specific Distribution of Reported Laboratory-Confirmed Dengue Cases 51
4.5.4 Age-Standardized Incidence of Reported Laboratory-Confirmed Dengue 53
4.6 Discussion 55
4.6.1 Epidemiological Forecast Insight 55
4.6.2 Limitations of the Analysis 56
4.6.3 Strengths of the Analysis 57
5 Current Surveillance, Prevention, and Control Measures 58
5.1 Overview 58
5.2 Brazil 64
5.2.1 Surveillance and Diagnosis 64
5.2.2 Vector Control 65
5.2.3 Immunization Recommendations and Infrastructure 66
5.3 India 68
5.3.1 Surveillance and Diagnosis 69
5.3.2 Vector Control 69
5.3.3 Immunization Recommendations and Infrastructure 70
5.4 Mexico 72
5.4.1 Surveillance and Diagnosis 73
5.4.2 Vector Control 74
5.4.3 Immunization Recommendations and Infrastructure 75
5.5 Singapore 78
5.5.1 Surveillance and Diagnosis 78
5.5.2 Vector Control 79
5.5.3 Immunization Recommendations and Infrastructure 79
5.6 Thailand 81
5.6.1 Surveillance and Diagnosis 81
5.6.2 Vector Control 82
5.6.3 Immunization Recommendations and Infrastructure 82
6 Unmet Needs Assessment and Opportunity Analysis 85
6.1 Overview 85
6.2 Unmet Needs Analysis 87
6.2.1 Unmet Need: Safe and Efficacious Vaccines 87
6.2.2 Unmet Need: An Improved Understanding of Dengue Immunity 89
6.2.3 Unmet Need: Reliable Immunological Correlates of Protection 90
6.2.4 Unmet Need: Country-Specific Immunization Program Preparedness 90
6.2.5 Unmet Need: Upgraded Vector Control and Surveillance Infrastructures 91
6.2.6 Unmet Need: Improved Diagnostic Tools 92
6.2.7 Unmet Need: High-Quality Animal Models 93
6.3 Opportunity Analysis 94
6.3.1 Opportunity: Develop a Single-Dose Dengue Vaccine 94
6.3.2 Opportunity: Further Elucidate the Role(s) of T Cells in Dengue Immunity 95
6.3.3 Opportunity: Streamline Vaccine Development with Innovative Clinical Trial Design 96
6.3.4 Opportunity: Partner with Public Health Stakeholders to Integrate Vaccines into Multifaceted Dengue Prevention Programs 96
6.3.5 Opportunity: Establish Country-Specific Vaccine Launch Strategies 97
6.3.6 Opportunity: Leverage Diagnostics to Demonstrate Vaccine Effectiveness Post-Licensure 98
7 Research and Development Strategies 100
7.1 Overview 100
7.2 Technological Approaches to Vaccine Development 100
7.2.1 Vaccine Antigen Selection 100
7.2.2 Tetravalent Vaccine Construction 102
7.3 Partnerships, Acquisitions, and Licensing Agreements 104
7.4 Clinical Trial Design 106
7.4.1 Current Clinical Trial Design 106
7.4.2 Inclusion of Representative Patient Populations in Clinical Trials 110
7.4.3 Demonstration of Protective Efficacy 111
7.4.4 Dengue Human Infection Model 112
8 Pipeline Assessment 114
8.1 Overview 114
8.2 Live-Attenuated Vaccines in Clinical Development 120
8.2.1 CYD-TDV 120
8.2.2 TAK-003 133
8.2.3 TV-003 139
8.3 Other Vaccines in Clinical Development 145
8.3.1 TDENV-PIV 145
8.3.2 DEN-80E 148
8.4 Vaccines in Preclinical Development 151
9 Pipeline Valuation Analysis 153
9.1 Clinical Benchmarking of Key Pipeline Vaccines 153
9.2 Commercial Benchmarking of Key Pipeline Vaccines 155
9.3 Competitive Assessment 157
9.4 Top-Line Five-Year Forecast 159
9.4.1 Brazil 163
9.4.2 India 165
9.4.3 Mexico 167
9.4.4 Singapore 168
9.4.5 Thailand 169
10 Appendix 172
10.1 Bibliography 172
10.2 Abbreviations 193
10.3 Methodology 197
10.4 Forecasting Methodology 197
10.4.1 Vaccinated Patients 197
10.4.2 Vaccination Coverage Rates 198
10.4.3 Vaccines Included in Each Class 198
10.4.4 Vaccine Launch Dates 198
10.4.5 General Pricing Assumptions 199
10.4.6 Individual Vaccine Assumptions 200
10.4.7 Pricing of Pipeline Vaccines 203
10.5 Physicians and Specialists Included in this Study 206
10.6 About the Authors 208
10.6.1 Analyst 208
10.6.2 Epidemiologist 208
10.6.3 Therapy Area Director 209
10.6.4 Global Head of Healthcare 209
10.7 About GlobalData 210
10.8 Disclaimer 210